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Abstract
Background: One of the defining moments of human life occurs early during
embryonic development, when individuals sexually differentiate into either male or
female. Perturbation of this process can lead to disorders/differences of sex devel-
opment (DSD). Chromobox protein homolog 2 (CBX2) has two distinct isoforms,
CBX2.1 and CBX2.2: the role of CBX2.1 in DSD has been previously established,
yet to date the function of the smaller isoform CBX2.2 remains unknown.
Methods: The genomic DNA of two 46,XY DSD patients was analysed using
whole exome sequencing. Furthermore, protein/DNA interaction studies were per-
formed using DNA adenine methyltransferase identification (DamID) to identify
putative binding partners of CBX2. Finally, in vitro functional studies were used to
elucidate the effect of wild‐type and variant CBX2.2 on selected downstream targets.
Results: Here, we describe two patients with features of DSD i.e. atypical exter-
nal genitalia, perineal hypospadias and no palpable gonads, each patient carrying
a distinct CBX2.2 variant, p.Cys132Arg (c.394T>C) and p.Cys154fs (c.460delT).
We show that both CBX2.2 variants fail to regulate the expression of genes
essential for sexual development, leading to a severe 46,XY DSD defect, likely
because of a defective expression of EMX2 in the developing gonad.
Conclusion: Our study indicates a distinct function of the shorter form of CBX2
and by identifying several of its unique targets, can advance our understanding of
DSD pathogenesis and ultimately DSD diagnosis and management.
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1 | INTRODUCTION
Disorder of sex development (DSD) combines a broad
spectrum of different phenotypes, defined as congenital
conditions in which the development of the gonad and/or
anatomical sex is atypical. Current data indicate that
approximately 1 in 4,500 birth exhibit genital anomalies,
for which in only around 50% of cases a causal gene vari-
ant can be found (Hughes et al., 2006). One of the genes
implicated in DSD is CBX2/M33, a member of the Poly-
comb group (PcG) proteins, that are conserved regulatory
factors initially discovered in Drosophila, best known for†These authors contributed equally to this work.
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their role in maintaining silent expression states of Hox
genes during development by regulating chromatin struc-
ture and chromosome architecture at their target loci.
Knocking out M33 in mice affected the development of
the genital ridge in both XX and XY embryos, suggesting
that it functions upstream of Sry. The majority of XY mice
showed sex reversal, whereas ovarian development was
impaired in XX animals (Katoh‐Fukui et al., 1998). Cbx2
is able to activate Sf1 expression during spleen and adrenal
development, suggesting that Cbx2 in mice has a role as
transactivator, distinct from its chromatin modifier function
(Katoh‐Fukui et al., 2006). Additionally, it has been shown
that forced expression of Sry or Sox9 in Cbx2 KO mice
could rescue to sex reversal in XY mice, although they pre-
sented with smaller gonads compared to WT mice (Katoh‐
Fukui et al., 2012). Katoh‐Fukui et al. concluded that Cbx2
may regulate testis determination by regulating, directly or
indirectly, Sry and additionally might influence gonadal
size through the regulation of other genes. Our group made
the discovery of a loss‐of‐function double heterozygote
CBX2.1 variant in a 46, XY girl with ovarian‐like tissue at
histology, normal uterus and external female genitalia, acci-
dentally diagnosed because of a discrepancy between pre-
natal karyotype and phenotype at birth. Functional studies
demonstrated that the CBX2.1 variant does not properly
bind to and does not adequately regulate the expression of
target genes essential for sex development such as SF1/
NR5A1. Our data identified CBX2.1 as essential for normal
human male gonadal development, suggested that it lies
upstream of SRY in the human sex development cascade
and identified a novel autosomal recessive cause of DSD.
From a more mechanistic point of view, we demonstrated
that CBX2.1 might have a role as transactivator, distinct
from its known function as chromatin‐modifier (Biason‐
Lauber, Konrad, Meyer, DeBeaufort, & Schoenle, 2009).
The function of the shorter isoform CBX2.2 is not yet
well‐explored. To study this isoform, we investigated the
c.394T>C (p.Cys132Arg) and the c.460delT (p.Cys154fs)
CBX2.2 variants, from two individuals with 46, XY DSD,
characterized by atypical external genitalia and dysgenetic
testis.
2 | MATERIALS AND METHODS
2.1 | Subjects
The study was approved by our institutional ethics commit-
tee and written informed consent was given.
2.1.1 | Patient one
The first patient, a white 9 months‐old girl born at term
and small for gestational age (2.300 g), was referred at the
outpatient clinic of Hospital das Clínicas of University of
Sao Paulo, with atypical external genitalia noticed at birth,
characterized by microphallus (2.5 cm), perineal hypospa-
dias and absence of palpable gonads. The karyotype was
46, XY. No Müllerian derivatives were found at pelvic
ultrasonography and retrograde uretrocistography showed a
blind vagina. At 2 years of age, a human chorionic gona-
dotropin (hCG) stimulation test was performed (two doses
of 2,000 U) and no testosterone increase and steroid pre-
cursor accumulation was found. Since childhood, the
patient showed a male behavior and after psychological
evaluation, changed to male social sex at 5 years of age.
He had a normal mental development. At 10 years of age
he was submitted to exploratory laparotomy which dis-
closed bilateral atrophic testis that were removed. Anato-
mopathological data showed dysgenetic testes characterized
by immature tubules with Sertoli cells only and a few atyp-
ical spermatogonias. No Leydig cells were identified in the
interstitium. By 17 years of age, he started androgen
replacement with testosterone esters. At this time his penile
size was 12 × 3 cm, serum LH level was 16 U/L, FSH
level was 54 U/L, and testosterone level was 230 ng/dl
14 days after exogenous testosterone (NV LH: 1,4–9,2 UI/
L; FSH: 1,0–12 UI/L. Total testosterone: 271–965 ng/dL).
2.1.2 | Patient two
The second patient was a white 34 years of age male at the
time of referral to the outpatient clinic of Hospital das
Clínicas of University of Sao Paulo. He presented with
atypical genitalia, characterized by microphallus (5.0 cm),
bilateral cryptorchidism, perineal hypospadias and scrotum
biphidus. 46, XY karyotype was confirmed by chromosome
analysis and laboratory evaluation showed hyperg-
onadotropic hypogonadism with LH levels of 10 U/L, FSH
levels of 78 U/L, and testosterone levels of 75 ng/dL. A
gonadectomy was performed, which revealed no gonadal
tissue on histology evaluation and furthermore, a hypoplas-
tic uterus was found. Genitoplasty, followed by testicular
prosthesis implant was performed. In the meantime, testos-
terone replacement was started by using testosterone cypi-
onate. The final penile length was 10 cm.
2.2 | Whole exome sequencing
Genomic DNA samples from both patients were analysed
by whole exome sequencing (WES) on a SureSelect
Human All Exon V.6.0 capture kit (Agilent, Santa Clara,
California, USA) and a HiSeq 4000 Sequencer (Illumina,
San Diego, California, USA). The reads were screened with
FastQ Screen (Babraham Bioinformatics, Cambridge, UK)
for possible contamination and a quality control has been
performed with FastQC (Babraham Bioinformatics). Read
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alignment has been performed with Bowtie 2 (Johns Hop-
kins University) against a human reference sequence
(GRCh37.p13/hg19). GATK HaplotypeCaller (Broad Insti-
tute) was used for calling SNPs and indels, and the aligned
data was visualized with the Integrative Genomics Viewer
(Broad Institute). Genes with known variants causing simi-
lar phenotypes were screened first (e.g. SRY, NR5A1/SF1,
DMRT1, TCF21, GATA4, DHH, FGF9, FGFR2, and
PGD2). Then, a list of 85 genes known to be involved in
46,XY and 46;XX DSD in general, was used to further
screen the WES data (Supporting information Table S1)
(Baetens et al., 2017). Finally, additional potential candi-
date variants were selected based on occurrence in the gen-
eral population (MAF < 0.5% in ExAC) and on the
predicted influence on the protein level (SIFT, PolyPhen,
Meta‐SNP, PhD‐SNP and SNAP).
2.3 | Genome‐wide analysis of CBX2.2
binding sites
In order to study the functional consequences of the vari-
ants, we first had to identify potential targets of CBX2.2 in
NT2/D1 (ATCC CRL‐1973) Sertoli‐like cells. Even though
they are pluripotent cells, these cells express most of the
important Sertoli‐cell markers (including SOX9, SF1 etc.)
(Knower et al., 2007). To analyse protein/DNA interaction
we used the DamID‐seq method that couples next‐genera-
tion sequencing to DamID (DNA adenine methyltransferase
identification) assay (Eid, Opitz, & Biason‐Lauber, 2015).
DamID is a methodology independent of antibodies, fixa-
tion, chromatin, shearing and other technically challenging
features of Chromatin Immuno Precipitation (ChIP), and is
a powerful tool for the mapping of genomic binding sites of
chromatin binding proteins (Vogel et al., 2006). Briefly,
human CBX2.2 cDNA (Origene, Rockville, Maryland,
USA) was amplified and cloned into a pENTR11 plasmid
(Invitrogen, Carlsbad, California, USA), then recombined
into the destination vector pLgw‐V5‐EcoDam‐RFC1 to gen-
erate pLgw‐V5‐EcoDam‐CBX2, using the Gateway LR
Clonase II enzyme mix according to the manufacturer's
directions (Invitrogen). Lentiviral packaging plasmids,
pRSV‐Rev (Addgene, plasmid 12253), pCMV‐dR8.2
(Addgene, plasmid 8455) and pMD2.G (Addgene plasmid
12259) were obtained from Addgene. DamID was per-
formed using a lentiviral transduction protocol as previously
described (Vogel, Peric‐Hupkes, & van Steensel, 2007),
using pLgw‐EcoDam‐V5‐CBX2 (EcoDam‐CBX2) or
pLgw‐V5‐EcoDam (Dam‐only). EcoDam‐CBX2 or Dam‐
only were transfected into HEK239T cells (ATCC CRL‐
11268) together with the packaging plasmids (pRSV‐Rev,
pCMV‐dR8.2, pMD2.G) using Metafectene (Biontex Labo-
ratories, Munich, Germany). 48 hr later, the supernatant
containing the lentivirus was harvested and added to NT‐
2D1 cells with 1 mg/ml polybrene (Santa Cruz Biotechnol-
ogy, Dallas, Texas, USA), in two consecutive rounds of
transduction. Two days after the first infection, genomic
DNA was isolated using the DNeasy blood and tissue kit
(Qiagen, Hilden, Germany). The isolated genomic DNA
was subject to DpnI digestion, ligation of DamID adaptors,
and DpnII digestion. Samples without addition of DpnI or
ligation adaptors served as negative controls. DpnII‐digested
fragments were used as templates to amplify methylated
genomic fragments. DNA libraries were prepared using the
TruSeq DNA LT Sample Prep Kit (Illumina) and the
libraries were sequenced on a HiSeq2000 sequencer (Illu-
mina). Cells expressing free Dam protein served as a con-
trol to correct for the unspecific DNA accessibility by Dam
alone and for sequencing biases.
2.4 | Immunofluorescence
Immunofluorescence was performed as previously reported
(Eid et al., 2010). Briefly, cells grown on cover slips were
pre‐extracted for 5 min on ice using 25 mM HEPES
(Sigma‐Aldrich, St. Louis, Missouri, USA) pH 7.4, 50 mM
NaCl (Acros Organics, Geel, Belgium), 1 mM EDTA
(Acros Organics), 3 mM MgCL2 (Sigma‐Aldrich), 300 mM
sucrose (Sigma‐Aldrich), and 0.5% Triton X‐100 (Sigma‐
Aldrich) before fixation in 4% (w/v) formaldehyde (Sigma‐
Aldrich) in PBS (Thermo Fisher Scientific, Waltham, Mas-
sachusetts, USA) for 15 min at room temperature (RT).
Cover slips were incubated overnight at 4°C with primary
antibodies anti‐V5 antibody (Santa Cruz Biotechnology)
and Alexa‐conjugated secondary antibodies (Invitrogen) for
1 hr at RT. The cover slips were mounted with Vec-
trashield (Vector Laboratories, Burlingame, California,
USA) containing DAPI. Images were acquired using a
Nikon eclipse Ni‐E microscope system.
2.5 | Functional analysis of the CBX2.2
mutants
We generated the p.Cys132Arg and p.Cys154fs variant
CBX2.2s by site directed mutagenesis of wild‐type cDNA
(Origene), according to the manufacture's manual (Quick-
change II Site‐Directed Mutagenesis Kit; Agilent).
The influence of WT and CBX2.2 variants on the
expression of selected candidate genes was studied by
means of quantitative real‐time PCR, performed with ABI
StepOnePlus Real‐Time PCR system, PCR products were
quantified fluorometrically using the KAPA SYBR FAST
master mix (KAPA Biosystems, Wilmington, Massachu-
setts, USA). The reference mRNA from cyclophilin was
used for data normalization. Primers sequence and qRT‐
PCR conditions for CBX2 isoforms and putative targets are
available upon request. All samples were run in triplicates
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and finally the normalized relative expression values
(2ΔΔCt ) of multiple independent experiments were plotted
against the relative expression values of the empty vector
which was set as 1. Unpaired t‐test was performed using
GraphPad Prism version 6.07 for Windows (GraphPad
Software, La Jolla, California, USA).
2.6 | Gene‐ontology enrichment analysis
ToppCluster was used for GO‐enrichment analysis of
CBX2.2 Dam‐ID target genes (Kaimal, Bardes, Tabar,
Jegga, & Aronow, 2010). GO‐enrichment permits to anal-
yse functional features of gene sets, clustering them by
their involvement in pathways related to Molecular Func-
tion, Biological Process and/or Cellular Component. GO‐
terms with p‐values ≤0.05 and more than five target genes
associated to the corresponding GO‐term were defined as
significant. CBX2.2 Dam‐ID target genes were clustered
depending on GO‐terms and visualized using spring‐embed
layout with Cytoscape v3.3.0 (Shannon et al., 2003).
3 | RESULTS
3.1 | Identification of CBX2.2 mutations
No variants in the coding sequence of genes potentially
causing a similar 46, XY DSD phenotype were found in
the WES data of both patients including SRY, TCF21,
GATA4, DHH, and PGD2. Patient one carries a DMRT1
variant (c.133T>A, p.Ser45Thr), a synonymous FGF9 vari-
ant (c.1284A>G, p.Ser149Ser) and a synonymous FGFR2
variant (c.1343A>G, p.Val232Val), all common in the gen-
eral population and predicted to be tolerable (Table 1). The
second patient carries the same DMRT1, FGF9, and
FGFR2 variants as patient one and two SF1/NR5A1 vari-
ants (c.437G>C, p.Gly146Ala, and c.499C>T, p.Pro125-
Pro), which are also common in the general population and
predicted to be tolerable (Table 1).
Screening the 85 genes implicated in 46, XY and 46XX
DSD, revealed a c.394T>C variant in CBX2.2, leading to a
p.Cys132Arg missense exchange in patient one and a
c.460delT deletion, leading to a p.Cys154fs frameshift in
patient two (Figure 1). The corresponding refSNP cluster
ID numbers are rs782325368 and rs552892809 respec-
tively. Both variants are rare, with a MAF on ExAC of
0.00001647 (p.Cys132Arg) and 0.001418 (p.Cys154fs) and
are predicted to be disease causing. CBX2.1 of patient one
carries two known allelic variants (rs71368052 and
rs3751956; Figure 1). ExAC predicts for CBX2 a pLI
(probability of LOF intolerance) of 0.95 (0 = gene tolerant
to LOF; 1 = gene completely intolerant to LOF).
The WES data were further analysed to find other rare
variants potentially causing the observed phenotype.
Besides CBX2.2, there are 27 and 30 other gene variants
in both patients, respectively, which were predicted to have
a high to moderate impact (missense‐variants, frameshift‐
variants, stop‐gained or splice acceptor/donor‐variants) and
are rare (MAF < 0.5%) (Supporting information Tables S2
and S3). The unavailability of the parents DNAs prevented
us from further filtering the variants. To analyze the puta-
tive relevance of these variants for the clinical phenotype,
with the help of Pathway Studio 11 (Elsevier), we searched
for connection between these genes with rare variants and
female gonad development, male gonad development,
gonad development, sex development, and sex determina-
tion. According to the literature, the only candidate gene
implicated in these processes is CBX2, allowing us to con-
clude that the CBX2.2 variants are the most likely candi-
dates for the observed phenotypes of the patients and
prompted us to further analyze these variants.
3.2 | Identification of CBX2.2 genomic
targets
To analyze the pathophysiological consequences of the
CBX2.2 variants, we had to face the challenge of not
knowing any targets for CBX2.2 and the consequent lack
of functional assays. To gain insights into the function of
CBX2.2 we applied the DamID‐seq method to identify its
direct targets. We prepared two replicates for CBX2.1 and
CBX2.2 fusion proteins or free Dam and sequenced the
DNA libraries separately. Immunofluorescence analysis
showed that the CBX2.2‐Dam construct correctly localized
to the nucleus (Figure 2). All pairs of replicates had highly
correlated read densities along the genome (Pearson corre-
lation coefficients >0.90, p‐value <2e‐16) and thus were
combined for the follow‐up analyses. Approximately 30%
of CBX2.2 binding peaks were found in the promoter
region, defined as 5Kb upstream of transcription start sites
(Supporting information Figure S1). After normalizing the
data to the controls, we identified 1901 enriched binding
sequences of CBX2.2 within the promoter region of vari-
ous genes, with a p‐value <1e‐5, of which 451 were shared
with CBX2.1 and were excluded from further analysis.
SOX9 is one of the common targets and has also been
excluded since it can be assumed that CBX2.1 might com-
pensate for CBX2.2 deficiency. In silico bioinformatic
analysis using Pathway Studio 11 (Elsevier) identified six
potential CBX2.2 unique targets. Target selection was
based on their reported putative involvement in sexual dif-
ferentiation, their role in human disease and animal models
or their specific expression in issues involved in sex devel-
opment (gonads, sex organs, hypothalamus, and pituitary),
as previously reported (Eid et al., 2015). Empty spiracles
homeobox 2 (EMX2) (Simeone et al., 1992), Male germ‐
cell associated kinase (MAK) which is exclusively
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expressed in testis and potentially important for spermato-
genesis (Matsushime, Jinno, Takagi, & Shibuya, 1990),
Homeobox A13 (HOXA13), a transcription factor which
has been linked to syndromes affecting genitourinary devel-
opment (Scott, Morgan, & Stadler, 2005), WD repeat‐con-
taining protein 77 (WDR77) also known as androgen
receptor‐associated protein, a 44‐kd protein interacting with
Polycomb and a component of a methyltransferase complex
involved in testis development and tumor formation (Liang
et al., 2007), Twist Family BHLH Transcription Factor 1
(TWIST1), a HAT binding protein that also interacts with
Polycomb proteins, was found to be related to androgen
TABLE 1 Variants found by whole exome sequencing in genes known to be related in 46, XX and 46, XY DSD for both patients
Genes Zygosity AA. Sub. SIFT PhD‐SNP SNAP Meta‐SNP PolyPhen ExAC (MAF) rs ID
Common mutations LEPR Hom Q223R 0.28 0.363 0.665 0.15 0.047 0.5103 rs1137101
LHX4 Het N328S 1 0.063 0.45 0.068 0.004 0.485 rs7536561
KISS1 Het P81R 0.28 0.016 0.61 0.075 0.972 0.3413 rs4889
AKR1C4 Hom Q250R 1 0.324 0.39 0.437 0.001 0.2055 rs17306779
WWOX Hom A179T 0.39 0.221 0.385 0.38 0.139 0.4507 rs11545029
AMH Hom V515A 0.77 0.044 0.345 0.044 0 0.9799 rs10417628
FBLN2 Het T854A 0.3 0.102 0.465 0.266 0.012 0.7364 rs9843344
SRD5A1 Het A39G — 0.091 0.255 0.044 0.001 0.6079 rs248793
MAP3K1 Hom D806N 0.19 0.396 0.555 0.112 0.092 0.5984 rs702689
MAP3K1 Hom V906I 0.76 0.137 0.51 0.059 0 0.7648 rs832582
PROP1 Het A142T 0.66 0.087 0.345 0.104 0.001 0.5113 rs4072924
ZFPM2 Het A403G 1 0.016 0.37 0.1 0 0.1146 rs11993776
ZFPM2 Het A1055V 0.16 0.093 0.535 0.17 0.046 0.01771 rs16873741
DMRT1 Het S45T 0.12 0.078 0.48 0.058 0.024 0.2678 rs3739583
HSD17B3 Het G289S 1 0.448 0.495 0.239 0 0.073306 rs2066479
FGFR2 Hom V232V — — — — — 0.7797 rs1047100
FGF9 Hom S149S — — — — — 0.8398 rs9509841
Patient one PBX1 Hom G21S 0.12 0.106 0.356 — 0.049 0.2977 rs2275558
AMH Hom S49I 0 0.206 0.625 0.137 0.068 0.7876 rs10407022
FSHR Het S654N 0.77 0.164 0.49 0.127 0 0.5727 rs6166
FSHR Het A281T 0.5 0.113 0.47 0.187 0.005 0.5446 rs6165
HHAT Het S182N 0.13 0.78 0.725 0.71 0.986 0.1439 rs2294851
INSL3 Hom T60A 1 0.051 0.115 0.05 0 0.6451 rs6523
CYP21A2 Het R103K 1 0.153 0.62 0.313 0.005 0.3341 rs75730897
POR Het A503V 0.37 0.164 0.435 0.215 0 0.3639 rs1057868
CYP11B1 Het R43Q 1 0.219 0.48 0.27 0 0.08037 rs4534
MAMLD1 Hom P334S 0.02 0.206 0.565 0.178 0.22 0.08321 rs41313406
MAMLD1 Hom N662S 0.19 0.202 0.635 0.213 0.007 0.1089 rs2073043
Patient two FBLN2 Hom N839K 0.74 0.299 0.28 0.166 0.627 0.001426 rs61731214
RXFP2 Het I580V 0.27 0.122 0.53 0.225 0.02 0.1487 rs17076657
NOBOX Het K664R 0.63 0.059 0.48 0.048 0.003 0.02763 rs77802098
ZFPM2 Het S657G 0.28 0.023 0.680 0.102 0.031 0.01258 rs28374544
NR5A1 Het G146A 0.5 0.187 0.43 0.246 0.001 0.1183 rs1110061
NR5A1 Het P125P — — — — — 0.02645 rs1110062
BMP15 Hom S5R 0.01 0.736 0.23 0.475 0.235 0.01587 rs113099187
Variants are sorted into common between both patients, variants specific for patient one and variants specific for patient two. The effects of the variants on the pro-
tein level were predicted by SIFT, PhD‐SNP, SNAP, Meta‐SNP, and PolyPhen. Scores predicting a damaging effect of the variant are colored in red. In order to
determine the occurrence in the general population, ExAC was used (rare: MAF < 0.005).
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receptor expression (Shiota et al., 2010) and Basonuclein 2
(BNC2), which has been linked to hypospadias and distal
urethral development (Bhoj et al., 2011). The analysis of
the expression of these genes was used as an assay for WT
versus mutant CBX2.2 function (see below).
3.3 | Gene ontology analysis of CBX2.2
targets
In order to retrieve a functional profile of the high‐through-
put gene sets and therefore better understand the underlying
biological processes, we performed an unbiased Gene
Ontology enrichment analysis of the DamID targets.
CBX2.2 targets showed an over‐representation of Gene
Ontology terms related to development and morphogenesis
(Figure 3), mainly in generic developmental terms like
embryo development, heart development, and neuron
development. Of particular interest for us, the analysis
showed that the CBX2.2 targets are also overrepresented
for the Gene Ontology term urogenital system develop-
ment, additionally demonstrating the involvement of
CBX2.2 in human sex development.
3.4 | Functional characterization of CBX2.2
variants
To independently validate our findings, we performed func-
tional studies using quantitative Real‐time PCR (RT‐qPCR)
for the six selected targets. For the first variant
(p.Cys132Arg), WT CBX2.2 increased the expression of
EMX2, MAK, HOXA13, WDR77, and BNC in NT2‐D1
cells significantly (p < 0.05) by 3.2, 1.9, 2.0, 1.5, and 1.6,
respectively, compared to the EV transfection (Figures 4
and 5). Using the CBX2.2 variant, the effect on EMX2,
MAK, and HOXA13 significantly (p < 0.05) diminishes to
expression values of 1.3, 1.0, and 0.8, with the expression
of the target genes behaving essentially like the control,
indicating that the effect is CBX2.2‐specific (Figure 4).
Overexpression of the first CBX2.2 variant (p.Cys132Arg)
increased the expression values for WDR77, BNC2, and
TWIST1, compared to the EV, to 1.1, 1.3, and 1.0 respec-
tively (Figure 5). However, they show no significant differ-
ence in expression under either WT or CBX2.2 variant
expression. Similarly, by transfecting of the CBX2.2 vari-
ant found in the second patient (p.Cys154fs), the effect on
the expression of EMX2, MAK, and HOXA13 also dimin-
ished significantly to expression values of 1.0, 0.8, and
0.7, again behaving essentially like the control (Figure 4).
The expression values for WDR77, BNC2, and TWIST1
changed to 3.5, 3.5, and 1.3, respectively, when overex-
pressing the second CBX2.2 variant (p.Cys154fs) (Fig-
ure 5). Similar to the first variant, there is no difference in
expression under either WT or the second CBX2.2 variant.
The CBX2.2 variant mRNAs were expressed at a level
similar to that of the wild‐type mRNA, suggesting that the
variants do not influence mRNA stability. In order to
ensure that the effect of CBX2.2 on EMX2 is isoform
FIGURE 1 Schematic representation
of the gene organization of both CBX2
isoforms. The CBX2.2 variants are depicted
in red (Patient one: p.Cys132Arg; Patient
two: p.Cys154fs). The two known SNPs
found in CBX2.1, g.‐52C>G (rs71368052)
and p.Leu414Leu (rs3751956), are depicted
in blue
FIGURE 2 Dam‐CBX2.2 localization in NT2‐D1 cells. NT2‐D1
cells were transfected with the pLgw‐EcoDam‐V5‐CBX2 (Dam‐
CBX2) and 48 hr later cells were detergent‐extracted and fixed. Dam‐
CBX2 was visualized by indirect immunofluorescence using a V5
antibody, nuclei were visualized by DAPI. Bar 10 μm
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specific, we performed overexpression studies of CBX2.1
in NT2‐D1 cells. Overexpression of CBX2.1 showed no
effect on EMX2 expression (Supporting information Fig-
ure S2).
4 | DISCUSSION
Our patients represent the first two known variants in
CBX2.2, the less known isoform of CBX2, associated to
46, XY DSD. In mice and men, loss‐of‐function of CBX2/
M33, causes male‐to‐female and 46, XY DSD (MIM
613080) respectively. CBX2 isoform 1 was shown to be a
transcription factor aside from its role as chromatin modi-
fier and we could established that CBX2 isoform 1 regu-
lates sex development by stimulating the male‐specific (e.g.
SF1 and SOX9) and inhibiting the female‐specific factors
(such as FOXL2) (Biason‐Lauber et al., 2009; Eid et al.,
2015). As for isoform 2, no function was known, mainly
because of the lack of animal models, as there is no evi-
dence of a CBX2.2 homologue in any other mammalian,
including other primates, and the absence of human
patients with CBX2.2 specific defects. The identification of
the first such 46, XY DSD patients allowed us to investi-
gate the function of CBX2.2.
Analysis of WES from the patients genomic DNA,
showed no rare (MAF < 0.005) and potentially damaging
variants related to 46, XY DSD, besides CBX2 (Table 1).
Furthermore, none of the 26 genes carrying rare variants
(MAF < 0.005) in both patients and are predicted to have
a high to moderate pathogenic impact, had any reported
link to sex development or had previously been mentioned
in DSD (Supporting information Tables S2, and S3) as
analyzed using Pathway studio. This allows us to state that
the CBX2.2 variants are the most likely cause for the
observed phenotype of the patients.
For the identification of potential CBX2.2 binding tar-
gets and subsequent functional analysis of CBX2.2 variant
function, we used the Sertoli‐like NT2/D1 cells, currently
still the best available human cell model to study Sertoli‐
cell development.
Using whole genome protein/DNA interaction and next
generation sequencing approaches, we identified a large
number of direct and unique potential targets of CBX2.2.
Of all the CBX2.2 specific targets, the most relevant for
sex development seems to be EMX2. EMX2 is a paired‐like
homeobox transcription factor, homologue of the Droso-
phila empty spiracle gene (Simeone et al., 1992). In the
mouse, Emx2 is essential for the development of several
organs/tissues, such as the kidney and the urogenital sys-
tem (Miyamoto, Yoshida, Kuratani, Matsuo, & Aizawa,
1997) and the central nervous system (CNS) (Galli et al.,
2002; Gangemi et al., 2001; Heins et al., 2001; O'Leary,
Chou, & Sahara, 2007). The absence of neurological
impairment usually associated to EMX2 variants (Granata et
al., 1997) or EMX2 haploinsufficiency (Piard et al., 2014)
in our patients, might suggest that CBX2.2 regulates
EMX2 expression specifically in the developing gonad and
FIGURE 3 Representation of Gene
Ontology (GO) enrichment analysis by
Cytoscape. Every dot represents a gene
related to the enriched GO‐terms, which
have been clustered depending on their
function. In orange are the GO‐terms
represented which are involved in
developmental processes, in red all GO‐
terms related to morphogenesis, in green
regulatory processes and in blue are the
GO‐terms involved in molecular function
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not the CNS. Emx2 XY KO mice have gonadal agenesis
(Miyamoto et al., 1997) due to proliferative defects of the
coelomic epithelium, which gives rise to Sertoli cells. This
implicated Emx2 in polarity of epithelial cells and their
transition to mesenchymal cells, most likely through EGFR
downregulation (Kusaka et al., 2010). Emx2 expression is
stimulated by Wnt and Bmp signalling in nervous system
development (Theil, Aydin, Koch, Grotewold, & Ruther,
2002) and it is repressed by HOXA10 during development
of the endometrium of mice and humans (Daftary & Tay-
lor, 2004; Troy, Daftary, Bagot, & Taylor, 2003) but very
little is known about the control of EMX2 in the develop-
ing gonad. In patients, deletions encompassing EMX2 cause
46,XY DSD ranging from hypospadias to gonadal dysgene-
sis (Piard et al., 2014), confirming its role in human gona-
dal development (MIM 269160). In human development,
EMX2 and CBX2 are simultaneously expressed in the
gonadal anlage at 7 weeks of gestation, i.e. prior to the
expression of SRY and testis determination, suggesting a
role in the formation of the early gonad (Ostrer, Huang,
Masch, & Shapiro, 2007). Subsequently, CBX2 is highly
expressed in both sexes at 8 GW (but higher in female than
male) then slightly decreases in male until basal, but still
detectable expression level at 18 GW (E. Lecluze, F. Chal-
mel, INSERM‐Rennes, personal communication). In agree-
ment with our data, Emx2 was also found downregulated
in Cbx2‐deficient mouse gonads (Katoh‐Fukui et al.,
2012). Based on our results, it is intriguing to hypothesize
that CBX2.2 variants that impair expression of EMX2
might lead to severe defects of gonadal development in 46,
XY individuals, similar to those individuals with EMX2
haploinsufficiency (Piard et al., 2014) and might explain
the severe testicular dysgenesis phenotype of the present
CBX2.2 deficient patients, different from the ovarian‐like
gonadal phenotype found in the 46,XY DSD CBX2.1 defi-
cient patient (Biason‐Lauber et al., 2009).
Another target of CBX2.2 is HOXA13, a homeobox
protein whose variants lead to and hand‐foot‐genital syn-
drome (also known as hand‐foot‐uterinesyndrome) or the
related Guttmacher syndrome, dominantly inherited
FIGURE 4 qRT‐PCR quantification of mRNA levels for the putative CBX2.2 targets EMX2, HOXA13, and MAK. NT2‐D1 cells were
transfected with empty vector (EV), wild‐type (WT) CBX2.2 or CBX2.2 variants (p.Cys132Arg or p.Cys154fs) from patient number one or
patient number two. Relative expression levels (2ΔΔCt ) of target genes were determined by qRT‐PCR after normalization to cyclophilin as an
endogenous control. Following WT CBX2 overexpression, the relative expression of EMX2, HOXA13 and MAK, was upregulated compared to
cells transfected with empty vector (EV). Introducing either variant of CBX2.2 (p.Cys132Arg or p.Cys154fs) into the cells showed an effect
comparable to negative control (i.e. no effect) on the expression of EMX2, HOXA13, and MAK, suggesting that failed regulation of these targets
might contribute to the pathophysiology of the disease. The data in all graphs are the average of three independent experiments, error bars
represent standard deviation from the mean (SEM) and values are expressed as relative to control = 1. (****) p < 0.0001; (***) p < 0.001;
(**) p < 0.01; (*) p < 0.05
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conditions characterized by Müllerian duct fusion defects
of varying degree in females and hypospadias in males
(Mortlock & Innis, 1997; Scott et al., 2005) (MIM
140000). Hoxa13 mutant mice show loss of Fgf8 and
Bmp7 expression and a decrease of the androgen receptor
in male genital organs (Morgan, Nguyen, Scott, & Stadler,
2003) implicating Hoxa13 in male sex differentiation and
might partly explain the patients’ phenotype. This suggests
that the mechanism of sex disorder in these CBX2.2‐defi-
cient patients might affect the sex developmental processes
primarily through impaired sex/gonadal development due
to failure to regulate EMX2.
Our data suggest that both CBX2 isoforms are impor-
tant for human sex development but they apparently have
different functions, as shown by the difference in gonadal
phenotype between loss‐of‐function of CBX2.1, which
leads to residual gonadal development (Biason‐Lauber et
al., 2009) and loss‐of‐function of CBX2.2, which leads to
the here described 46, XY gonadal dysgenesis. DamID‐Seq
analysis underlines the difference in function, since
CBX2.1 and CBX2.2 only share about 25% of direct bind-
ing sequences.
There are other examples of the involvement of multiple
isoforms in gonad development, the most prominent one
being Wilms Tumor 1 (WT1). WT1 codes for different iso-
forms, most important for gonad development are
WT1−KTS and WT1+KTS, which differ only by the three
amino acids Lysine (K), Threonine (T) and Serine (S). It
has been shown that WT−KTS is required for gonad pri-
mordium survival, while the +KTS form seems mainly
involved in the determination of the male pathway (Wil-
helm & Englert, 2002).
The same appears to be the case for CBX2, as each iso-
form presents with distinct functions during gonad develop-
ment. While CBX2.2 seems to be important for early
bipotential gonad development, CBX2.1 seems to be
mainly involved in testis determination. Nothing is known
about the transcriptional control of CBX2, which could fur-
ther help to elucidate the reason behind the different func-
tion of the isoforms and their spatiotemporal expression.
However, alternative splicing and the existence of multiple
isoforms with different functions during sex development
and development in general, appear to be an important
mechanism to control gene/protein cascades and
FIGURE 5 qRT‐PCR quantification of mRNA levels for the putative CBX2.2 targets WDR77, BNC2, and TWIST1. NT2‐D1 cells
transfected with empty vector (EV), wild‐type (WT) CBX2.2 or CBX2.2 variants (p.Cys132Arg or p.Cys154fs) from patient number one or
patient number two. Relative expression levels (2ΔΔCt ) of target genes were determined by qRT‐PCR after normalization to cyclophilin as an
endogenous control. Following WT CBX2 overexpression, the relative expression of WDR77 and BNC2 was up‐regulated compared to cells
transfected with empty vector (EV). Both CBX2.2 variants had stimulatory effects similar to those of WT CBX2.2 on the expression level of
WDR77, BNC2, and TWIST1, likely excluding them from the mechanism of disease. The data in all graphs are the average of three independent
experiments, error bars represent standard deviation from the mean (SEM) and values are expressed as relative to control = 1. (*) p < 0.05
SPROLL ET AL. | 793
differentiation pathways. Functional studies and analysis of
spatiotemporal expression‐differences for isoforms could
expand our current knowledge about sex development and
further characterization of how CBX2 and its targets fit into
an ever expanding sex developmental network can impact
our understanding of DSD pathogenesis and ultimately
DSD diagnosis and management.
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